# ClinicalTrials.gov record NCT01782261

> PeptideScanner retained ClinicalTrials.gov record NCT01782261 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-10-11, and PeptideScanner's reviewed identity mapping was liraglutide.

- Evidence object: `story:clinicaltrials-gov-nct01782261-liraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2016-10-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01782261-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01782261-liraglutide-v1.json
- Content SHA-256: `8213ce37389b772285ab94210a3a512dd8c042898f0586fa07e34518fc75473b`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT01782261 ([`ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a`](#source-ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01782261 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-10-11, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a`](#source-ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01782261 at 2026-07-30T21:34:56.513Z. Its registry update date was 2016-10-11, and PeptideScanner's reviewed identity mapping was liraglutide. ([`ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a`](#source-ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a`](#source-ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a))

## Sources

<a id="source-ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a"></a>
- **ClinicalTrials.gov record NCT01782261 · retained source version 2016-10-11:faa1f2f8ee8a6d6651fd6333f3ca3379db5c92bb34f08120775d077c97b7ba1e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01782261) (`ctg-observation-nct01782261-2016-10-11-faa1f2f8ee8a`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01782261." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct01782261-liraglutide-v1.json SHA-256: 8213ce37389b772285ab94210a3a512dd8c042898f0586fa07e34518fc75473b.